The purpose of this study was to evaluate the correlation between best-corrected visual acuity (BCVA) and macular thickness in patients with persistent macular edema treated with a dexamethasone intravitreal drug delivery system (dexamethasone DDS).
In a randomized, multicenter, controlled, parallel-group, dose-ranging study, patients with macular edema lasting at least 90 days despite treatment were randomized to observation or treatment with 350- or 700-μg dexamethasone DDS. Macular thickness was assessed in 80 patients using optical coherence tomography. Best-corrected visual acuity was measured using Early Treatment Diabetic Retinopathy Study methodology.
At baseline, macular thickness was significantly inversely correlated with BCVA (r = −0.406, P < 0.001). Patients treated with 350- or 700-μg dexamethasone DDS showed a significant decrease in macular thickness from baseline to Day 90 (P = 0.002). In the 700-μg dexamethasone DDS treatment group, there was a modest inverse correlation between changes in macular thickness from baseline to Day 90 and improvement in BCVA (r = −0.530, P = 0.009). In the 350-μg dexamethasone DDS treatment group, the correlation was weaker and not statistically significant (r = −0.206, P = 0.304).
The correlation between baseline BCVA and macular thickness in patients with persistent macular edema was modest. Improvement in BCVA after treatment with 700-μg dexamethasone DDS was consistent with changes in macular thickness measured using optical coherence tomography.
In patients with persistent macular edema treated with an intravitreal 700-mg dexamethasone drug delivery system, improvement in best-corrected visual acuity was modestly correlated with a decrease in macular thickness measured by optical coherence tomography
From the *Department of Ophthalmology, Stanford University School of Medicine, Stanford, California; †Wills Eye Institute, Philadelphia, Pennsylvania; ‡Department of Ophthalmology, University of California, Irvine, Irvine, California; §William Beaumont Hospital, Royal Oak, Michigan; ¶Fundus Photograph Reading Center, University of Wisconsin, Madison, Wisconsin; **The Eye Institute, Medical College of Wisconsin, Milwaukee, Wisconsin; ††Eisai Medical Research Inc., Ridgefield Park, New Jersey; and ‡‡Allergan, Inc, Irvine, California.
This study was sponsored by Allergan, Inc, Irvine, California. M.S.B., J.A.H., B.D.K., G.A.W., M.I., M.D., and D.V.W. have no proprietary interest in the study treatments or in Allergan, Inc. They serve as consultants for Allergan, Inc. D.V.W. is a consultant for and a former employee of Allergan, Inc. C.C. was an employee of Allergan, Inc at the time this work was done, and S.M.W. is a present employee of Allergan, Inc.
Reprint requests: Mark S. Blumenkranz, MD, Department of Ophthalmology, Stanford University School of Medicine, Boswell A157, 300 Pasteur Dr, Stanford, CA 94305; e-mail: email@example.com